Oncolys BioPharma (TSE:4588) EPS (Basic): 円-34.35 (TTM As of Dec. 2025)

Author: Vera Yuan Vera Yuan
Vera Yuan
Vera Yuan
Director of Data and Quant Analytics at GuruFocus
Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Reviewed by: Charlie Tian Charlie Tian
Charlie Tian
Charlie Tian
Founder & CEO of GuruFocus
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.

TSE:4588 Oncolys BioPharma Inc TSE:4588
40 GF Score
Price 円2,501.00
GF Value 円363.33
Valuation Significantly Overvalued
! 5 Warning Signs
View Full Analysis

What is Oncolys BioPharma EPS (Basic)?

Oncolys BioPharma TSE:4588 -0.83% 40 EPS (Basic) is 円-34.35 as of Dec. 2025. GuruFocus rates TSE:4588 with a GF Score™ of 40/100 and a GF Value™ of 円363.33 (Significantly Overvalued). The stock has 5 warning signs investors should review.

Oncolys BioPharma's basic earnings per share (Basic EPS) for the three months ended in Dec. 2025 was 円0.00. Its basic earnings per share (Basic EPS) for the trailing twelve months (TTM) ended in Dec. 2025 was 円-34.35.

Oncolys BioPharma's EPS (Diluted) for the three months ended in Dec. 2025 was 円0.00. Its EPS (Diluted) for the trailing twelve months (TTM) ended in Dec. 2025 was 円-34.35.

Oncolys BioPharma's EPS without NRI for the three months ended in Dec. 2025 was 円0.00. Its EPS without NRIearnings per share without non-recurring items for the trailing twelve months (TTM) ended in Dec. 2025 was -34.35.

During the past 3 years, the average EPS without NRI Growth Rate was -6.00% per year. During the past 5 years, the average EPS without NRI Growth Rate was 6.60% per year. During the past 10 years, the average EPS without NRI Growth Rate was 1.70% per year. Please click Growth Rate Calculation Example (GuruFocus) to see how GuruFocus calculates Wal-Mart Stores Inc (WMT)'s revenue growth rate. You can apply the same method to get the EPS without NRI Growth Rate using EPS without NRI data.

During the past 13 years, Oncolys BioPharma's highest 3-Year average EPS without NRI Growth Rate was 21.20% per year. The lowest was -77.80% per year. And the median was -3.80% per year.

Oncolys BioPharma  (TSE:4588) EPS (Basic) Explanation

EPS is the single most important variable used by Wall Street in determining the earnings power of a company. But investors need to be aware that Earnings per Share can be easily manipulated by adjusting depreciation and amortization rate or non-recurring items. That's why GuruFocus lists EPS without NRI, which better reflects the company's underlying performance.

Be Aware

Compared with Earnings per share, a company's cash flow is better indicator of the company's earnings power.

If a company's earnings per share is less than cash flow per share over long term, investors need to be cautious and find out why.

Oncolys BioPharma EPS (Basic) Related Terms

Oncolys BioPharma EPS (Basic) Historical Data

* Premium members only.

The historical data trend for Oncolys BioPharma's EPS (Basic) can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Oncolys BioPharma EPS (Basic) Chart

Oncolys BioPharma Annual Data
Trend Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23 Dec24 Dec25
EPS (Basic)
Get a 7-Day Free Trial Premium Member Only Premium Member Only -95.50 -66.31 -108.92 -77.17 -80.00

Oncolys BioPharma Quarterly Data
Dec20 Mar21 Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24 Jun24 Dec24 Mar25 Jun25 Dec25 Mar26
EPS (Basic) Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 0.00 -32.66 -20.19 0.00 -14.16
TSE:4588
40GF Score
Oncolys BioPharma Inc TSE:4588
EPS (Basic) is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

Oncolys BioPharma EPS (Basic) Calculation

EPS (Basic) is a rough measurement of the amount of a company's profit that can be allocated to one share of its stock. Basic earnings per share (EPS) do not factor in the dilutive effects on convertible securities.

Oncolys BioPharma's Basic EPS for the fiscal year that ended in Dec. 2025 is calculated as

Basic EPS (A: Dec. 2025 )=(Net Income-Preferred Dividends)/Shares Outstanding (Basic Average)
=(-2058.049-0)/25.726
=-80.00

Oncolys BioPharma's Basic EPS for the quarter that ended in Dec. 2025 is calculated as

Basic EPS (Q: Dec. 2025 )=(Net Income-Preferred Dividends)/Shares Outstanding (Basic Average)
=(0-0)/25.726
=0.00

EPS (Basic) for the trailing twelve months (TTM) ended in Dec. 2025 adds up the quarterly data reported by the company within the most recent 12 months, which was 円-34.35

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Frequently Asked Questions Learn more about EPS (Basic) →
What does a EPS (Basic) of 円-34.35 mean?
Oncolys BioPharma (TSE:4588) has a EPS (Basic) of 円-34.35 as of Dec. 2025. Earnings per share (basic) equals net income divided by the standard, non-diluted average shares outstanding. View historical data on Oncolys BioPharma and its competitors.
Is Oncolys BioPharma's EPS (Basic) too high?
Oncolys BioPharma's current EPS (Basic) is 円-34.35. Overall, Oncolys BioPharma has a GF Score™ of 40/100 and is considered Significantly Overvalued, reflecting its overall financial health beyond just this single metric.
How does Oncolys BioPharma's EPS (Basic) compare to VRTX and REGN?
Oncolys BioPharma's EPS (Basic) of 円-34.35 can be compared against companies in the Biotechnology industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good EPS (Basic) for a Biotechnology company?
A good EPS (Basic) depends on the Biotechnology industry context. However, EPS (Basic) should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high EPS (Basic) mean?
A high EPS (Basic) can signal that a stock is expensive relative to its fundamentals. Earnings per share (basic) equals net income divided by the standard, non-diluted average shares outstanding. View historical data on Oncolys BioPharma and its competitors. Oncolys BioPharma's current EPS (Basic) is 円-34.35. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Oncolys BioPharma stock overvalued right now?
Based on GuruFocus' analysis, Oncolys BioPharma (TSE:4588) is currently considered Significantly Overvalued. The stock's GF Value™ is 円363.33, compared to a current price of 円2,501.00 — trading 588.4% above its estimated fair value. The current EPS (Basic) is 円-34.35. Oncolys BioPharma's overall GF Score™ is 40/100 with 5 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is EPS (Basic) calculated?
EPS (Basic) is calculated from a company's financial statements. For Oncolys BioPharma (TSE:4588), the current EPS (Basic) is 円-34.35 as of Dec. 2025. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Is Oncolys BioPharma (TSE:4588) Overvalued in 2026?

Based on GuruFocus' analysis, Oncolys BioPharma stock appears to be overvalued. The current stock price of 円2,501.00 is trading 588.4% above its estimated GF Value™ of 円363.33. GuruFocus considers Oncolys BioPharma to be Significantly Overvalued.

Key valuation signals for TSE:4588:

  • EPS (Basic): 円-34.35
  • GF Value™: 円363.33 vs. price of 円2,501.00 (588.4% above fair value)
  • GF Score™: 40/100 with 5 warning signs

No single metric tells the full story. See the TSE:4588 stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.

Oncolys BioPharma Business Description

Address 4-1-28 Toranomon, Toranomon Towers Office, Minato-ku, Tokyo, JPN, 105-0001
Oncolys BioPharma Inc develops pharmaceutical products. The company is a biopharmaceutical company focused on developing therapies for cancer treatment. Their product pipeline includes various drug candidates such as Telomelysin (OBP-301) and OBP-702, aimed at addressing unmet medical needs in oncology. The company targets healthcare providers and institutions involved in cancer care and research.
40GF Score

Get the complete analysis for TSE:4588

EPS (Basic) is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

円2,501.00
Price
円363.33
GF Value